Hybrigen, Bionomics Ink Intent to Study Breast Cancer Gene Targets | GenomeWeb

NEW YORK, Sept. 20 – Hybrigen and Bionomics Limited have signed a letter of intent to negotiate a partnership to study a pair of genes linked to breast cancer, the companies said on Thursday.

The target-discovery program will study the genes, TSG18 and BNO1, using genetic data identified and patented by Adelaide, Australia-based Bionomics, the firms said in a statement. For its part, Hybrigen, based in Dallas, will use its own proprietary proteomic technologies to discover drug targets that interact with those genes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."